MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S.

The global statistics are terrifying. Prostate cancer is the fourth most common cancer in all populations, the second most common cancer among men worldwide, and ranks first in Europe, where a third ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending drug abiraterone, in clinical trial results presented by scientists from ...

ORLANDO, Fla. (Ivanhoe Newswire) - Prostate cancer is the second leading cause of death in men right behind heart disease. Patients with this cancer often don’t find out until the disease has advanced ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic ...

Former President Joe Biden and other older men may not be getting routine prostate cancer screenings but his recent Stage 4 diagnosis raises questions about whether that's always the best choice.

Of all the health conditions facing men as they get older, there is no doubt that prostate cancer is the most widely discussed, emotive and challenging. It is also fairly controversial, given the ...

Celebrities have sent prostate cancer’s public profile soaring in recent years. But with accusations that some men are being ...